Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Powles, Thomas, Csőszi, Tibor, Özgüroğlu, Mustafa · The Lancet Oncology · 2021